Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?

TWST stock surged 13.57% to $162.49 on Monday, driven by a new partnership with Eli Lilly’s TuneLab R&D platform. The collaboration allows TuneLab users to access Twist Bioscience’s antibody characterization data services under preferred protocols and pricing. The deal aims to enhance antibody drug discovery by linking wet-lab data with AI models like AbLab.

What Happened

Twist Bioscience announced an agreement to provide antibody characterization data to Lilly’s TuneLab, including support for AbLab, an antibody developability prediction model. This collaboration expands TuneLab’s access to experimental data, which will be used to train AI models and improve candidate selection in drug discovery. The partnership was highlighted in multiple reports, emphasizing its potential to streamline Lilly’s R&D pipeline and validate Twist’s role in the biotech innovation ecosystem.

The stock opened at $147.50, up 3.1% from the prior close, and climbed steadily throughout the session. The rally reflects investor optimism about the strategic value of the partnership and its potential to increase demand for Twist’s services. Recent coverage also noted the company’s role in strengthening AI-driven drug discovery and next-generation sequencing capabilities.

What The Data Shows

The stock has gained 12.7% over the last eight sessions, rising from $125.41 to $141.30 before Monday’s move. With a market cap of $8.7 billion, the company remains unprofitable, reporting an EPS TTM of -2.23 and a net margin of -31.7%. However, revenue grew 19.2% TTM. Monday’s volume of 0.8 million shares was 0.5 times the 3-month average, suggesting a moderate but meaningful participation level. The stock closed at $161.45, just below its 52-week high of $155.44, having printed a fresh 52-week high on the session.

What To Watch

The stock’s performance will likely depend on the breadth of coverage and investor reaction to the partnership’s progress. No earnings date is scheduled in the near term, but continued collaboration developments with TuneLab may influence coverage and market sentiment.